EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical trial of evenamide, a schizophrenia treatment, in Japan. The trial will evaluate patients with treatment-resistant schizophrenia who have demonstrated poor or insufficient response to at least two antipsychotic treatments. It will study the efficacy, safety and tolerability of evenamide as […] The post EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan appeared first on Pharmafile.

Continue reading →